Early access availability of ProteoVue Software
ProteoVue is part of broader set of innovation initiatives, including the Company’s recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance
-Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was submitted to BioRxiv, demonstrating the capabilities of its proprietary bioinformatics tool called ProteoVue, for detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled “Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS),” highlights the transformative potential of Quantum-Si’s Platinum® benchtop instrument in advancing proteomics research and applications. The full preprint publication will be available soon on the BioRxiv website.
The Company previously announced a collaboration relationship with NVIDIA as part of its Investor & Analyst Day on November 20, 2024 which introduced the Proteus platform and other advancements.
Quantum-Si invites researchers and potential collaborators to early access of the ProteoVue workflow. To learn how you can become part of the journey toward deeper understanding and groundbreaking discoveries, visit: Protein Variant Applications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.